Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events

NACompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

November 13, 2014

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
AnticoagulantsThromboembolismHemorrhage
Interventions
OTHER

Measurement of Plasma Concentrations of NOACs

Plasma concentrations of dabigatran, rivaroxaban or apixaban will be measured using High Performance Liquid Chromatography (HPLC) coupled with tandem mass spectrometry (MS/MS). Blood samples will be taken in an EDTA tube and rapidly centrifugated. Plasma will be aliquoted and frozen at minus 80 degrees Celsius for later analysis.

GENETIC

Identification of ABCB1 polymorphisms coding for P-gp

To investigate the existence of a relation between polymorphisms of ABCB1 and plasma concentrations of new oral anticoagulants, the SNaPshot® Multiplex System will be used enabling multiplexing of SNPs (single nucleotide polymorphisms) of the ABCB1 gene (namely rs4148738, rs2235046, rs1128503, rs10276036, rs1202169, rs1202168, rs1202167).

Trial Locations (1)

25000

CHU Besancon, Besançon

All Listed Sponsors
collaborator

Etablissement Français du Sang

OTHER

lead

Centre Hospitalier Universitaire de Besancon

OTHER

NCT02103101 - Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events | Biotech Hunter | Biotech Hunter